Papp L Roy & Associates raised its stake in Amgen, Inc. (NASDAQ:AMGN) by 3.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,566 shares of the medical research company’s stock after purchasing an additional 447 shares during the period. Papp L Roy & Associates’ holdings in Amgen were worth $2,446,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund lifted its position in shares of Amgen by 20,103.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after purchasing an additional 31,268,677 shares in the last quarter. Capital International Investors grew its holdings in Amgen by 301.4% during the 3rd quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock valued at $2,299,506,000 after buying an additional 8,329,861 shares in the last quarter. Capital World Investors purchased a new position in Amgen during the 3rd quarter valued at about $952,900,000. BlackRock Inc. boosted its position in shares of Amgen by 2.0% during the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after acquiring an additional 906,568 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Amgen by 36.2% during the 3rd quarter. AQR Capital Management LLC now owns 2,907,575 shares of the medical research company’s stock valued at $602,711,000 after acquiring an additional 773,506 shares during the last quarter. 79.18% of the stock is owned by institutional investors.
In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the transaction, the director now directly owns 14,988 shares in the company, valued at approximately $2,830,933.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 6,000 shares of company stock worth $1,144,120. 0.27% of the stock is owned by company insiders.
Shares of AMGN stock traded down $3.47 on Wednesday, hitting $184.58. The company’s stock had a trading volume of 36,350 shares, compared to its average volume of 2,205,140. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79. Amgen, Inc. has a fifty-two week low of $165.22 and a fifty-two week high of $210.19. The company has a market capitalization of $115.83 billion, a PE ratio of 12.79, a price-to-earnings-growth ratio of 2.34 and a beta of 1.21.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.16. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same quarter in the prior year, the firm posted $2.89 EPS. On average, analysts forecast that Amgen, Inc. will post 13.96 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.14%. Amgen’s dividend payout ratio (DPR) is 40.28%.
AMGN has been the topic of a number of recent research reports. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Mizuho set a $208.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Friday, April 12th. BidaskClub lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. Cowen reiterated a “buy” rating and set a $234.00 price target on shares of Amgen in a research report on Tuesday, February 26th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $221.00 price objective on shares of Amgen in a research note on Monday, April 1st. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Amgen currently has a consensus rating of “Hold” and an average target price of $209.11.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Discover Your Risk Tolerance
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.